⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 1, 2017European Journal of EndocrinologyOpen Access

Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies

Xiaoping Luo Ling Hou Li Liang Guanping Dong Shuixian Shen Zhuhui Zhao Chun Gong Yu‐Chuan Li Minlian Du Zhe Su Hongwei Du Chaoying Yan

View Full Paper

Ask AI

Bookmark

Share

Abstract

Jintrolong PEG-rhGH at a dose of 0.2 mg/kg/week for 25 weeks is effective and safe for GHD treatment and is non-inferior to daily rhGH.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Luo et al. (2017) studied this question.

synapsesocial.com/papers/69d9fcfd0f32475823a3cb4d https://doi.org/10.1530/eje-16-0905

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiencyOriginal Research · 2013 · 21 citations
2A Multicenter Study of the Efficacy and Safety of Sustained Release GH in the Treatment of Naive Pediatric Patients with GH DeficiencyOriginal Research · 2001 · 84 citations
3Long-acting pegylated human GH in children with GH deficiency: a single-dose, dose-escalation trial investigating safety, tolerability, pharmacokinetics and pharmacodynamicsOriginal Research · 2011 · 48 citations
4PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug DeliveryReview · 2011 · 419 citations
5Lipoatrophy in GH deficient patients treated with a long-acting pegylated GHRCT · 2009 · 73 citations

More related papers

Pegylated Long-Acting Human Growth Hormone Is Well-Tolerated in Healthy Subjects and Possesses a Potential Once-Weekly Pharmacokinetic and Pharmacodynamic Treatment Profile2010
Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns2014
PEGylation of somatropin (recombinant human growth hormone): Impact on its clearance in humans2008

More from European Journal of Endocrinology

BMI as a partitioning factor for estradiol and estrone reference intervals in middle-aged men and postmenopausal womenMon,
Machine Learning Quantifies Within-Subject Facial Change in AcromegalyThu,